New England Journal of Medicine· 2015Q1

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel et al.

9,485citations
Q1SCImago
2015year

Short summary

Nivolumab significantly improved overall survival (median 12.2 months vs. 9.4 months) and response rates (19% vs. 12%) compared to docetaxel in patients with advanced nonsquamous non-small-cell lung cancer previously treated with chemotherapy.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine